[link removed]
[link removed] [link removed]
View web version ([link removed])
[link removed]
We may soon have a third vaccine. Here’s what you need to know about the Johnson & Johnson shot
The results of a late-stage clinical trial for a new COVID-19 vaccine from Johnson & Johnson were hailed as good news, even though the company reported that its one-shot vaccine had a lower efficacy rate than its two-shot rivals — Moderna and Pfizer-BioNTech — which are already being administered to people across the US.

We asked and answered key questions about the new vaccine and how it compares to the others.

Read the full story. ([link removed])

Related:
-Johnson & Johnson vaccine, developed with Beth Israel, is 66 percent effective globally ([link removed])
-Wouldn’t you rather get vaccinated by your own doctor? Alas, most doctors can’t get doses ([link removed])
Subscribe to BostonGlobe.com ([link removed])
------------------------------------------------------------
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list. ([link removed])
------------------------------------------------------------

============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** Like us ([link removed])
** Follow us ([link removed])
You received this message because you signed up for Breaking News Alerts.

Copyright © 2021 The Boston Globe, All rights reserved.

Our mailing address is:
The Boston Globe
1 Exchange Place Suite 201
Boston, MA 02109-2132
USA

** unsubscribe from this list ([link removed])

** Manage Your Account ([link removed])
| ** Terms of Service ([link removed])
| ** Privacy Policy ([link removed])
| ** Help Center ([link removed])
| ** Advertise (mailto:[email protected]?subject=Advertising+in+BostonGlobe.com)